views

SourceBio International (SBI) has announced proposed cancellation of its, AIM, stock market listing and a “tender offer pursuant to which up to 11,071,810 ordinary shares (representing approximately 14.9 per cent. of the existing share capital of the company) would be purchased by the company at a price of 115 pence per ordinary share”. With the shares currently 110p and there 74,183,038 in issue, why is this proposed and what does it mean for shareholders?

NEWSFLOW

views

Previously writing on laboratory services company SourceBio International (SBI), last year with the shares at 137.5p I concluded to avoid with changes to travel PCR testing expected to impact. The shares last closed at 111p and today a “Trading Update and Proposed Cancellation”-titled announcement.

NEWSFLOW

NEWSFLOW

views

Its shares having commenced last week at 166.5p and slipped to a last close 162.5p, today from SourceBio International (SBI) a “Statement re Changes to COVID-19 Travel Testing”...and the shares currently at 137.5p.

NEWSFLOW

views

Hello Share Mates. It might seem a little late in the day to commend to your further attention a company which tests for the virus. But a lot more of that sort of thing will be needed before the vaccines finally squash the disease. Unlike some companies which are thrashing around in the market, SourceBio International (SBI) has seen a big demand for its laboratory testing.